ClinicalTrials.gg
RecruitingNCT07324629Updated Aug 12, 2026

Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma

A Phase 2 interventional study of Sacituzumab tirumotecan in Thymic Carcinoma, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Thymoma with a site in China — 17 open to participants now, 18 under way, 3 of them phase 3. Thymoma · China.

Planned enrollment
28th of 31
30 · median 64
Started
2026
with 3 others
Phase 2
12 of 36
7 open now
Primary completion
2028-04
later than 12 of 17 live
Registered
32nd of 36
by date

Among the 36 studies in Thymoma with a site in China, this one is the 28th largest by planned enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 12 of the 17 other live ones, and was the 32nd registered.

Thymoma

133 studies on the registry are indexed under Thymoma; 37 are open to participants now.

Browse Thymoma studies →

Open to participants now

17 of the 36 studies in Thymoma with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Thymoma studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Thymoma with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are:

  • How effective is drug Sac-TMT in treating Thymic Carcinoma?
  • What adverse events (AEs) do participants have when taking drug Sac-TMT?

Participants will:

  • Progress after at least one platinum-based chemotherapy treatment.
  • Take drug Sac-TMT every 2 weeks.
  • Take tumor response assessments every 6 weeks.
03

Conditions studied

  • Thymic Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged ≥ 18 to ≤ 75 years at the time of signing the Form;
  • Participants with or cytologically confirmed thymic carcinoma, and locally advanced or thymic carcinoma who are not suitable for curative intent therapy;
  • Participants with advanced thymic carcinoma who have progressed after at least one prior platinum-based chemotherapy;
  • Able to provide a tumor tissue sample at the time of or after the diagnosis of locally advanced or metastatic tumor;
  • At least one measurable target lesion that has not received radiotherapy according to v1.1;
  • performance status score of 0 or 1;
  • Expected survival ≥ 12 weeks;
  • Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  • Participants with or cytologically confirmed thymoma or thymic neuroendocrine tumor;
  • Participants with known to meninges, brainstem metastases, spinal cord metastases and/or compression, active or untreated ;
  • Participants with other malignant tumors within 3 years prior to the first dose;
  • Presence of any of conditions or risk factors related to cardiovascular and cerebrovascular diseases;
  • Uncontrolled systemic disease as judged by the investigator;
  • History of interstitial lung disease/noninfectious pneumonitis requiring therapy;
  • Clinically severe pulmonary impairment due to lung disorder;
  • Presence of active or ;
  • Known active tuberculosis;
  • Known to the study drug or any of its components.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sac-TMT 5mg/kg Q2W

    Drug: Sacituzumab tirumotecan

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    To evaluate the objective response rate (ORR) of sac-TMT as assessed by the investigator based on RECIST v1.1.

    Time frame: From enrollment to the end of treatment at 24 months

Secondary outcomes

  1. PFS

    To evaluate the progression-free survival (PFS) as assessed by the investigator based on RECIST v1.1.

    Time frame: From enrollment to the end of treatment at 24 months

  2. OS

    To evaluate the overall survival (OS) of sac-TMT in participants with locally advanced or metastatic thymic carcinoma with treatment failure after platinum-based therapy.

    Time frame: From enrollment to the end of treatment at 24 months

  3. Incidence and severity of AEs and SAEs, and abnormal laboratory values.

    To evaluate the safety of sac-TMT in participants with locally advanced or metastatic thymic carcinoma.

    Time frame: From enrollment to the end of treatment at 24 months

  4. DCR

    Duration of response (DOR) as assessed by the investigator based on RECIST v1.1.

    Time frame: From enrollment to the end of treatment at 24months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.

Of 32 phase 2 interventional studies under Thymoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 96. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 7, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Oct 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07324629
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Mar 13, 2026
Primary completion
Apr 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Yan Qing
Contact
qingyan@kelun.com
028-67255495

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion